tion. In contrast, the cognitive deficits in patients with mood disorders appears to be more state-related as they tend to be at least partially responsive to antidepressant medication [2] [3] [4] .
As previously reported [5] we found augmentation of antipsychotic treatment with an antidepressant (citalopram) results in a significant reduction of the severity of subsyndromal depressive symptoms (SSD) among middle-aged and older patients with schizophrenia or schizoaffective disorder. We found no significant effects of citalopram on the Folstien Mini-Mental Status Examinations (MMSE) [6] , but the MMSE is a course measure designed to stage the severity of dementia; it may not be sensitive to the less severe cognitive deficits that tend to characterize schizophrenia [1] . In this report, we examine the hypothesis that treatment augmentation with citalopram among patients with schizophrenia/schizoaffective disorder and SSD will improve cognitive functioning as measured by a more comprehensive and sensitive battery of neuropsychological tests than provided by the MMSE alone.
Methods

Participants
The 198 participants had DSM-IV-TR schizophrenia or schizoaffective disorder and SSD (defined by having 2-4 of the 9 DSM-IV-TR symptoms of a major depressive episode present most of the time for at least 2 weeks as well as a Hamilton Depression Rating Scale (HDRS 17-item score 1 8) [7] . Data were collected as part of an NIMH-funded 12-week double-blind randomized placebo-controlled trial of augmentation of a primary antipsychotic medication with citalopram to decrease depressive symptoms in schizophrenia/schizoaffective disorder and SSD [5] . Participants were recruited through the University of California, San Diego (UCSD) Advanced Center for Innovation in Services and Interventions Research on Late-Life Psychoses and the VA Cincinnati Health Care System, Cincinnati, Ohio. The institutional review boards for these facilities reviewed and approved the study protocol, and all participants provided written informed consent prior to enrollment. Between February 2001 and January 2006, 106 participants were recruited from the San Diego site and 92 from the Cincinnati site. For full inclusion and exclusion criteria please refer to Zisook et al. [5] . Briefly, the study included people with schizophrenia or schizoaffective disorder and SSD who were aged 6 40 years and who did not have any other Axis I disorder within 2 months of enrollment. All participants were outpatients, competent to consent and diagnoses were established via the Structured Clinical Interview for DSM-IV-TR (SCID) [8] administered by the clinical research coordinator.
Study Treatments
Participants were randomly assigned in this double-blind trial to either citalopram (20 mg/day) or placebo augmentation of their current stable antipsychotic treatment. The study dose of citalopram was allowed to be increased or decreased according to clinical response and/or side effects, within the range of 10-40 mg/day at the discretion of the blinded study physician. Potential participants currently on any medication to treat depression who consented were tapered and discontinued from this medication for at least 4 weeks before entering the trial. Some participants (n = 8, 4%) were allowed to continue on a stable low-dose antidepressant medication, only if prescribed for the treatment of insomnia or chronic pain.
Measures
Descriptive Information. Demographic and clinical history information was collected via self-report and/or review of available records.
Severity of Psychopathology. Subjects were assessed with the 17-item HDRS [7] and the Calgary Depression Rating Scale (CDRS) [9] , as well as the Positive and Negative Syndrome Scale (PANSS) for schizophrenia [10] .
Cognitive Functioning. Neurocognitive functioning was evaluated with the following test battery at baseline and at 12 weeks: MMSE [6] , Digit Span Distractibility Test [11] , letter and category fluency [12] , the Trail-Making Test (part A) [13, 14] , the Continuous Performance Test -identical pairs [15] , Digit-Symbol-Coding [16] , Symbol Search [16] and Letter-Number Sequencing [16] . This battery was selected to provide a general assessment of cognitive abilities known to be affected by schizophrenia and/or depression. Raw scores were converted to standardized z-scores using the baseline means and SDs for each measure (scaled such that higher scores represent better functioning), and the mean z-score across measures for each subject was used as an index of overall cognitive functioning.
Statistical Analysis
All variables were examined for violation of assumptions required for parametric analyses. No site-by-group interactions were significant, so this term was dropped from any further analyses. Two-way analyses of variance (ANOVAs) were used to evaluate differences in clinical and demographic characteristics. Cochran-Mantel-Haenszel tests compared the characteristics across treatments. Differences between treatment groups on the cognitive composite score were compared using analysis of covariance (ANCOVA). The main dependent variable in the ANCOVA model was the final cognitive composite score at the endpoint of the study, while the independent variables were baseline-symptom severity and treatment group. To determine whether cognition moderated the effects of depression treatment, we used linear modeling that included endpoint CDRS or HDRS as the dependent variables, and treatment, baseline cognition, treatment by baseline cognition, baseline CDRS and site as independent variables [17] . Significance was defined as p ! 0.05 (2-tailed).
Results
Ninety-four of the participants were randomized to the placebo, 104 were randomized to citalopram. The average dose of citalopram given throughout the trial was 28.9 mg (SD = 9.8, range 10-40) per day. The demographic and clinical characteristics among the 2 groups have been reported elsewhere [5] , but, as briefly summarized in table 1 , other than a higher proportion of widowed patients than the placebo group, there were no significant demographic or clinical differences between groups. As reported previously [5] , citalopram augmentation resulted in significantly more improvement in depressive symptoms relative to the changes seen in the placebo group over the 12-week course of the study.
Means and SDs for the cognitive composite z-scores as well as for the 10 component neurocognitive measures are shown in table 2 . The cognitive composite score showed good internal consistency (Cronbach alpha = 0.843). As illustrated in figure 1 , from the baseline observation to the last observation at 12 weeks, there were no differences between the 2 treatments in terms of cognitive functioning -as measured by the cognitive composite [F(1,133) = 0.072, p = 0.789] for the whole sample, or when the participants with schizoaffective disorder were excluded from the analysis [F(1,85) = 0.058, p = 0.811].
There was no relationship between the scores on the HDRS or the CDRS and the cognitive composite at baseline (r = -0.01, p 1 0.05 and r = 0.12, p 1 0.05, respectively). Furthermore, the linear model evaluating moderation indicated that the interaction between cognition and treatment group did not detect differences between scores on the HDRS [F(1,145) = 0.456, p = 0.501] or the CDRS 
Discussion
Contrary to our hypothesis, citalopram augmentation to treat SSD among patients with schizophrenia did not yield significant improvements in cognitive function, even though, as described elsewhere [5] , citalopram augmentation did result in a significant improvement in depressive and negative symptoms relative to the placebo. The lack of observed cognitive effects of treating SSD in schizophrenia may speak to the general tenacity of cognitive deficits in schizophrenia [1] , but may also reflect the relatively moderate-to-mild severity of depressive symptoms in this sample. As this was a study of SSD in schizophrenia, we did not include patients with major depression; it is possible that cognitive deficits among patients with more severe depressive symptoms would be more responsive to antidepressant treatment.
Another potential limitation of the study is the 12-week timeframe. Although 12 weeks is longer than most studies of antidepressant treatment, it is possible that cognitive improvements lag behind improvements in affective symptoms. Other limitations included the restricted age range, the absence of first-break or inpatient participants, and the fact that participants were reported to be on several different antipsychotics (see Zisook et al. [5] ). It is possible that schizophrenia and schizoaffective disorder are more related to bipolar than to unipolar depression [18] [19] [20] . Thus, in future studies it would be useful to consider whether mood stabilizers, which have been found to be effective augmentation agents for pa- tients with schizophrenia [21] , might provide cognitive improvement in schizophrenic patients with SSD.
Although citalopram did not positively impact cognition, it is important to note that we did not find any detrimental effects either. Given the positive effects of citalopram augmentation on SSD, and the importance of the latter in terms of patient-suffering and quality of life, it remains important for clinicians to be alert to depressive symptoms in schizophrenia patients and to consider direct treatment of these symptoms as well as addressing the psychotic symptoms of the disorder [5] . In addition, as cognitive impairment has been consistently shown to be the most robust predictor of functional disability in schizophrenia [22] , there is a continued need to find a direct means of effectively treating attendant cognitive deficits [23, 24] . To resolve the symptoms of psychosis or depressive symptoms that occur simultaneously are only the initial steps in trying to improve the overall quality of life and functional ability of schizophrenia patients. The future of treatment must prioritize enhancing cognition in order to fully realize the potential recovery of people with schizophrenia.
